X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ANV419 is a powerful, IL-2Rβ selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2. It stimulates the expansion of natural killer (NK) and cytotoxic CD8+ T cells in patients with multiple myeloma.
Lead Product(s): ANV419,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
ANV419, is a selective interleukin-2 (IL-2) receptor agonist which can selectively promote the function of immune effector cells, making it a potential treatment for a range of cancer types.
Lead Product(s): ANV419,Pembrolizumab
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
In this heavily pre-treated population, 5 patients continue to receive ANV419 treatment. At ANV419 doses ≥108 µg/kg, 75% of patients achieved at least disease stabilization (5 SD, 1 PR).
Lead Product(s): ANV419
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment.
Lead Product(s): ANV419
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Proceeds from this financing will enable the Company to pursue multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. ANV419, is designed to signal through the IL-2 beta/gamma receptor and overcome known challenges of human IL-2.
Lead Product(s): ANV419
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $119.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 16, 2021
Details:
Anaveon received Clinical Trial Application has been accepted by the Spanish Agency of Medicines and Medical Devices (AEMPS) to conduct a Phase I/II study evaluating the safety and clinical activity of its lead product, ANV419, as a monotherapy in advanced solid tumors.
Lead Product(s): ANV419
Therapeutic Area: Oncology Product Name: ANV419
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
